Starpharma (ASX:SPL) reports DEP HER2-lutetium shows potent anticancer effect
Latest Company News - Finance News Network
English - March 16, 2021 00:00 - 34 seconds - 1000 KBBusiness News News Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Clean TeQ Holdings (ASX:CLQ) awarded contract to upgrade Oman plant
Next Episode: 5GN (ASX:5GN) set for $3 million Intergrid deal
16 Mar 2021 - Starpharma (ASX:SPL) says its second radiopharmaceutical candidate, DEP HER2-lutetium, achieved potent and durable anticancer activity, with complete tumour regression, outperforming Herceptin labelled with lutetium, in a breast cancer model.